Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Protalix ( (PLX) ).
On May 21, 2026, Protalix BioTherapeutics posted a new corporate presentation outlining recent regulatory and commercial progress, including a $25 million milestone payment from partner Chiesi. The company highlighted European Commission and U.K. approvals in March and May 2026 for an every-four-weeks Elfabrio dosing regimen for stable adults with Fabry disease, which halves annual infusion days versus standard bi-weekly therapy.
The presentation underscored clinical data supporting Elfabrio’s extended dosing, including the BRIGHT study, long-term extension results, and pharmacokinetic analyses, suggesting maintained efficacy and safety with reduced treatment burden. Protalix also emphasized its seasoned leadership and board, revenue-generating ProCellEx-based manufacturing, and a strategic shift to expand its rare disease pipeline, particularly in renal indications and with PRX-115 for uncontrolled gout now in Phase 2, signaling a move into its next phase of growth.
The most recent analyst rating on (PLX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Protalix stock, see the PLX Stock Forecast page.
Spark’s Take on PLX Stock
According to Spark, TipRanks’ AI Analyst, PLX is a Neutral.
The score is led by improving fundamentals and balance sheet strength (strong TTM growth/margins, positive cash flow, and low leverage) plus supportive valuation (very low P/E). These are partially offset by weak technicals (bearish trend signals despite oversold readings) and execution/timing risks discussed on the earnings call (product-sales variability, higher R&D, and reimbursement/enrollment visibility).
To see Spark’s full report on PLX stock, click here.
More about Protalix
Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing protein therapeutics for rare diseases, notably enzyme replacement therapies such as Elfabrio for Fabry disease and Elelyso for Gaucher disease. The company leverages its proprietary plant cell-based ProCellEx platform and maintains global partnerships with Chiesi Global Rare Diseases, Pfizer, and Brazil’s Fiocruz to manufacture and market its therapies.
Protalix is also advancing a pipeline of rare disease candidates, with a three-year goal of building 5–7 programs from discovery to clinic. Its lead pipeline asset, PRX-115 for uncontrolled gout, has shown potentially differentiated Phase 1 data and is now in an actively enrolling Phase 2 trial, positioning the company for future growth beyond its current commercial products.
Average Trading Volume: 951,886
Technical Sentiment Signal: Sell
Current Market Cap: $161.9M
See more insights into PLX stock on TipRanks’ Stock Analysis page.